Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

News Daily News

Even After Multivessel or LM PCI, Routine Stress Testing Adds Nothing

Yael L. Maxwell

March 01, 2024

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

DCB in Diabetes Show Promising Long-term Outcomes: BASKET-SMALL 2

L.A. McKeown

August 16, 2021

News Daily News

Sleep Apnea Awareness, Treatment May Improve Some CVD Outcomes: AHA

L.A. McKeown

June 23, 2021

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Shelley Wood

January 14, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Daily News

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Michael O'Riordan

October 18, 2018

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos

Shelley Wood

September 28, 2016

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Daily News

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Todd Neale

July 06, 2016

News Daily News

Los Fibroateromas de Casquete Fino Podrían Explicar los Malos Resultados PCI de los Pacientes Diabéticos

Todd Neale

July 06, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

Advertisement

Even After Multivessel or LM PCI, Routine Stress Testing Adds Nothing

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

DCB in Diabetes Show Promising Long-term Outcomes: BASKET-SMALL 2

Sleep Apnea Awareness, Treatment May Improve Some CVD Outcomes: AHA

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Los Fibroateromas de Casquete Fino Podrían Explicar los Malos Resultados PCI de los Pacientes Diabéticos

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content